

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)ATTY DOCKET NO.
038007/0111SERIAL NO.
Unassigned

09005634

APPLICANT
Peter K. LAWFILING DATE
January 9, 1998GROUP
Unassigned

Date Submitted to PTO: January 9, 1998

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|--------------------|---------|-----------------|-------|----------|-------------------------------|
| ↓ | A1 | 4,542,148 | 09/1985 | Hosokawa et al. | 514 | 356 | |
| ↓ | A2 | 5,139,481 | 08/1992 | Faustman et al. | 604 | 49 | |
| ↓ | A3 | 4,154,652 | 05/1979 | Sawamura et al. | 195 | 1.8 | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
|---|----|--------------------|---------|---------|-------|----------|-----------------------|
| ↓ | A4 | 93/17697 | 09/1993 | WIPO | | | |
| ↓ | A5 | 95/14079 | 05/1995 | WIPO | | | |
| ↓ | A6 | 96/38544 | 12/1996 | WIPO | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | |
|---|-----|--|--|
| ↓ | A7 | | Morgan, "Cell and Gene Therapy in Duchenne Muscular Dystrophy", Human Gene Therapy, Vol. 5, pp. 165-173, (1994) |
| ↓ | A8 | | Maltsev et al., "Embryonic Stem Cells Differentiate in vitro into Cardiomyocytes Representing Sinusnodal, Atrial and Ventricular Cell Types", Mech. Devl., Vol. 44, pp. 41-50, (1993) |
| ↓ | A9 | | Koh et al., "Long-term Survival of AT-1 Cardiomyocyte Grafts in Syngeneic Myocardium", Am. J. Physiol, Vol. 264, pp. 1727-1733, (1993) |
| ↓ | A10 | | Watson et al., "Working Toward Human Gene Therapy: Recombinant DNA", New York, W.H. Freeman & Co., pp. 576, (1992) |
| ↓ | A11 | | Enrikin et al., "Drugs in Muscular Dystrophy of the Chicken: Corticosterone-21 Acetate; Nerve & Muscle, (1984) |

EXAMINER

Teresa Tounback

DATE CONSIDERED

1-14-99

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)ATTY DOCKET NO.
038007/0111SERIAL NO.
Unassigned

09005034

APPLICANT
Peter K. LAWFILING DATE
January 9, 1998GROUP
Unassigned

Date Submitted to PTO: January 9, 1998

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | |
|----------|-----------------|--|---|
| b6 | A19 | | C.A. Bonsett, Duchenne Muscular Dystrophy-A Rational Approach to Disease Comprehension and Therapy", |
| | | | Indiana Medicine, March, 1986 |
| | A20 | | Lee et al., "Mdx Transgenic Mouse: Restoration of Recombinant Dystrophin to the Dystrophic Muscle", |
| | | | Human Gene Therapy, (1993) |
| | A21 | | Rowland, "Prednisone in Duchenne Muscular Dystrophy", |
| | | | The Lancet, February 15, 1975 |
| | A22 | | Wolfe et al., "Direct Gene Transfer into Mouse Muscle in Vivo", |
| | | | Science, Vol. 274, pp. 1465-1468, (1990) |
| | A23 | | Folkers et al., "Treatment of Preclinical Muscular Dystrophy with Coenzyme Q", |
| | | | Excerpta Med. Int. Service, Vol. 334, p. 158, (1974) |
| | A24 | | Law, "Reduced Regenerative Capability of Dystrophic Mouse Muscle", |
| | | | Exp. Neurol, Vol. 60, pp. 231-43, (1978) |
| | A25 | | Young et al., "Histochemical Analysis of Newly Synthesized and Accumulated Sulfated Glycosaminoglycans |
| | | | During Musculogenesis in the Embryonic Chick Leg.", J. Morph, Vol. 201, pp. 85-103, (1989) |
| | A26 | | Jackman et al., "Catheter Recordings of Accessory Atrioventricular Pathway Activation..." |
| | | | From Cell to Bedside, pp. 491-502, (1990) |
| | A27 | | Soonpaa et al., "Formation of Nascent Intercalated Disks Between Grafted Fetal Cardiomyocytes and Host |
| | | | Myocardium", Science, pp. 264-98, (1994) |
| | A28 | | Huard et al., "Human Myoblast Transplantation in Immunodeficient and Immunosuppressed Mice: Evidence of |
| | | | Rejection Muscle Nerve", Vol. 17, pp. 224-34, (1994) |
| | A29 | | Roy et al., "Antibody Formation After Myoblast Transplantation in Duchenne-Dystrophic Patients, Donor |
| | | | HLA Compatible", Transpl. Proc., Vol. 25, pp. 995-7, (1993) |
| | A30 | | Huard et al., "Human Myoblast Transplantation Between Immunohistocompatible Donors and Recipients |
| | | | Produces Immune Reactions", Transpl. Proc., Vol. 24, pp. 3049-51, (1992) |
| ✓ | A31 | | Law et al., "Pathogenesis and Treatment of Hereditary Muscular Dystrophy", |
| | | | Kakulas BA, Mastalgia, pp. 101-18, (1990) |
| EXAMINER | Paenda Kounback | | DATE CONSIDERED 1-14-99 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)ATTY DOCKET NO.
038007/0111

SERIAL NO.

~~Unassigned~~ 09 005 034APPLICANT
Peter K. LAWFILING DATE
January 9, 1998GROUP
Unassigned

Date Submitted to PTO: January 9, 1998

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--------------------------|-----|---|
| b/s | A32 | Law et al., "Myoblast Injection Method Regulates Cell Distribution and Fusion", |
| | | Transpl. Proc. in Press |
| | A33 | Law et al., "New Muscle Transplant Method Produces Normal Twitch Tension in Dystrophic Muscle", |
| | | Nerve, Vol. 2, pp. 356-63 |
| | A34 | Law et al., "Feasibility, Safety, and Efficacy of Myoblast Transfer Therapy on Duchenne Muscular Dystrophy Boys", |
| | | Cell Transplantation, Vol. 1, pp. 235-44, (1992) |
| ↓ | A35 | Law et al., "Cell Transplantation as an Experimental Treatment for Duchenne Muscular Dystrophy", |
| | | Cell Transplantation, Vol. 3, pp. 485-503, (1993) |
| ✓ | A36 | Peterson, "Chimaera Mouse Study Shows absence of Disease in Genetically Dystrophic Muscle", |
| | | Nature, Vol. 248, pp. 561-4, (1974) |
| | A37 | Hogan et al., "Manipulating the Mouse Embryo", |
| | | A Laboratory Manual, Cold Spring Harbor Laboratory, (1986) |
| b/s | A38 | Cox et al., "Overexpression of Dystrophin in Transgenic MDX Mice Eliminates Dystrophic Symptoms Without |
| | | Toxicity", Nature, Vol. 364, pp. 725-9, (1993) |
| | A39 | Milhorat, "Therapy in Muscular Dystrophy Medical Annals of the District of Columbia", |
| | | Vol. 23, pp. 15, (1954) |
| | A40 | Wood, "New Therapeutic Directions in Duchenne Muscular Dystrophy Following Discovery of Dystrophin", |
| | | Pathogenesis and Therapy of Duchenne and Becker, Muscular Dystrophy, Raven Press, pp. 85-99 |
| | A41 | Annals of the District of Columbia |
| | | Vol. 23, pp. 15, (1954) |
| | A42 | Van Meter, "Progressive Muscular Dystrophy", |
| | | Calif. Med., Vol. 79, pp. 297-99, (1990) |
| | A43 | Nakahara, "Studies on Progressive Muscular Dystrophy", |
| | | Arzneim. Forsch., Vol. 15, pp. 591-95, (1965) |
| ✓ | A44 | Drachman et al., "Prednisone in Duchenne Muscular Dystrophy", |
| | | Lancet, Vol. 2, pp. 1409-12, (1974) |
| EXAMINER Brenda Brunback | | DATE CONSIDERED 1-14-99 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)ATTY DOCKET NO.
038007/0111SERIAL NO.
Unassigned

09 005 034

APPLICANT
Peter K. LAWFILING DATE
January 9, 1998GROUP
Unassigned

Date Submitted to PTO: January 9, 1998

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | |
|----------|---------------|--|---|
| b6 | A45 | | Coakley et al., "Mazindol in Duchenne Muscular Dystrophy", |
| | | | Lancet, Vol. 1, No. 8578, pp. 184, (1988) |
| | A46 | | Munsat et al., "Prednisone in Duchenne Muscular Dystrophy", |
| | | | Lancet, Vol. 1, pp. 276-77, (1985) |
| | A47 | | Siegel et al., "Failure of Corticosteroid in the Treatment of Duchenne (Pseudo-Hypertrophic) Muscular |
| | | | Dystrophy", I.M.J., Vol. 145, pp. 32-33, (1974) |
| | A48 | | Acsadi et al., "Human Dystrophin Expression in MDX Mice After Intramuscular Injection of DNA Constructs", |
| | | | Nature, Vol. 352, pp. 815-18, (1991) |
| | A49 | | Neumeyer et al., "Arterial Delivery of Myoblasts to Skeletal Muscle", |
| | | | Neurology, Vol. 42, pp. 2258-62, (1992) |
| | A50 | | Smith et al., "Genes Transferred by Retroviral Vectors into Normal and Mutant Myoblasts in Primary Cultures |
| | | | Are Expressed in Myotubes", Mol. & Cell. Biol., Vol. 10, pp. 3268-71, (1990) |
| 1 | A51 | | Hyde et al., "Correction of the Ion Transport Defect in Cystic Fibrosis Transgenic Mice by Gene Therapy", |
| | | | Nature, Vol. 362, pp. 250-55, (1993) |
| | A52 | | Hoffman et al., "Dystrophin: The Protein Product of the Duchenne Muscular Dystrophy", |
| | | | Locus. Cell, Vol. 51, pp. 919-28, (1987) |
| | A53 | | Chen et al., "Dystrophin Cytochemistry in MDX Mouse Muscles Injected with Labeled Normal Myoblasts", |
| | | | Cell Transplantation, Vol. 1, pp. 17-22, (1992) |
| | A54 | | Partridge et al., "Conversion of MDX Myofibers From Dystrophin-Negative to Positive by Injection of Normal |
| | | | Myoblasts", Nature, Vol. 337, pp. 116-17, (1989) |
| | A55 | | Gussioni et al., "Normal Dystrophin Transcripts Detected in Duchenne Muscular Dystrophy Patients After |
| | | | Myoblast Transplantation", Nature, Vol. 365, pp. 435-38, (1992) |
| | A56 | | Huard et al., "Myoblast Transplantation Produced Dystrophin-Positive Muscle Fibers in a 16-Year-Old Patient |
| | | | with Duchenne Muscular Dystrophy", Clin. Sci., Vol. 81, pp. 287-88, (1991) |
| ✓ | A57 | | Huard et al., "Human Myoblast Transplantation: Preliminary Results of 4 Cases", |
| | | | Muscle Nerve, Vol. 15, pp. 550-60, (1992) |
| EXAMINER | Kendra Kunkel | | DATE CONSIDERED 1-14-99 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)ATTY DOCKET NO.
038007/0111SERIAL NO.
~~Unassigned~~ 09005034APPLICANT
Peter K. LAWFILING DATE
January 9, 1998GROUP
Unassigned

Date Submitted to PTO: January 9, 1998

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----|-----|---|
| bbs | A58 | Law et al., "Dystrophin Production Induced by Myoblast Transfer Therapy in Duchenne Muscular Dystrophy", |
| | | Lancet, Vol. 336, pp. 114-15, (1990) |
| | A59 | Law et al., "Myoblast Transfer for Duchenne Muscular Dystrophy", |
| | | Acta Paediatrica, Japan, Vol. 33, pp. 206-15, (1991) |
| | A60 | Law et al., "Myoblast Transfer Therapy for Duchenne Muscular Dystrophy", |
| | | Advances in Clinical Neurosciences, Vol. 2, pp. 463-70, (1992) |
| | A61 | Law et al., "Pioneering Development in Myoblast Transfer Therapy", Muscular Dystrophy Research, |
| | | Elsevier Science Publishers, pp. 109-11, (1991) |
| | A62 | Law et al., "Long-Term Improvement in Muscle Function, Structure and Biochemistry Following Myoblast |
| | | Transfer in DMD", Acta Cardiologica, Vol. 3, pp. 281-301, (1991) |
| | A63 | Law, "Beneficial Effects of Transplanting Normal Limb-Bud Mesenchyme Into Dystrophic Mouse Muscles", |
| | | Nerve and Muscle, Vol. 5, pp. 619-27, (1982) |
| | A64 | Law et al., "Histoincompatible Myoblast Injection Improves Muscle Structure and Function of Dystrophic Mice", |
| | | Transplantation Proceedings, Vol. XX, No.3, Supp. 3, pp. 1144-19, June (1988) |
| | A65 | Law, "Myoblast Transfer Improves Muscle Genetics/Structure/Function and Normalizes the Behavior and Life |
| | | Span of Dystrophic Mice", Myoblast Transfer Therapy |
| | A66 | Law et al., "Normal Myoblast Injections Provide Genetic Treatment for Murine Dystrophy", |
| | | Nerve & Muscle, Vol. 11, pp. 525-33, (1988) |
| | A67 | Barr et al., "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts", |
| | | Science, Vol. 254, pp. 1507-9, (1991) |
| ✓ | A68 | Karpati et al., "Dystrophin is Expressed in MDX Skeletal Muscle Fibers After Normal Myoblast Implantation", |
| | | American journal of Pathology, Vol. 135, No. 1, July (1989) |
| | | |
| | | |
| | | |
| | | |

EXAMINER

Brenda Beemack

DATE CONSIDERED

1-14-99

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.